Helicobacter pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: Intervention 1: The sequential regimen is a dual therapy including omeprazole (Dr. Abidi Co.) 1mg/Kg plus amoxicillin (Farabi Co.) 25mg/Kg (both twice daily) given for the first 5 days
Treatment - Drugs
Intervention 1: The sequential regimen is a dual therapy including omeprazole (Dr. Abidi Co.) 1mg/Kg plus amoxicillin (Farabi Co.) 25mg/Kg (both twice daily) given for the first 5 days followed by a t
Intervention 2 (Control): Triple therapy with omeprazole (DR. Abidi Co.) 1mg/Kg(30 days), plus amoxicillin (Farabi Co.) 25mg/Kg (10 days)and metronidazole (Tehranshimi Co.) 10mg/Kg (10 days).all drugs
Sponsors
Vice chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 14 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Gastrointestinal symptoms including epigastric tenderness,abdominal pain without reason or at night, pain increase after feeding,early satiety, weight loss without reason, recurrent vomiting, iron deficiency anemia without reason 2- Helicobacter pylori infection documented by pathology or rapid urease test 3- Age below 14 and above 2 years Exclusion criteria: 1- Drug consumption including proton pomp inhibitor, histamine blockers, bismuth containing drugs and antibiotics during last 4 weeks 2- History of gastric surgery 3- Hypersensitivity to antibiotics 4-Previous known underlying diseases including renal failure or endocrine diseases
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication. Timepoint: Before intervention and 2 months after intervention (1 month after cessation of treatment). Method of measurement: Pathology or rapid urease test (Baharafshan Co.) on the specimen taken during endoscopy before treatment and fecal antigen test of Helicobacter pylori (G.E.N.E.S.I.S , UK) after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment Side Effects. Timepoint: 2 Weeks After Beginning of Treatment. Method of measurement: Questionnaire.;Endoscopic presentations of Helicobacter pylori. Timepoint: Before intervention. Method of measurement: Endoscopic view recorded in questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasood Unesian
Tehran University of Medical Sciences
Outcome results
None listed